Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PORTOLA VALLEY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a national nonprofit and leading sponsor of tick-borne disease research in the US, today announced the...
-
ISRL USA and AI Infrastructure Partners Sign MOU to Build America's First Dedicated Semiconductor SubFAB R&D Facility
-
SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) – Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company...
-
• Former Oxford Pro-Vice-Chancellor for Innovation and former Head of Biology at GSK to lead company’s R&D• Longstanding Scientific Advisory Board Chair steps into an expanded leadership role to...
-
BOTHELL, Wash., April 21, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high...
-
According to BCC Research, the market is expected to grow from $30.2 billion in 2024 to $49.5 billion by 2030 at a CAGR of 8.8%.
-
ATCC and the Broad Institute developed drug-resistant cancer models to better understand how lung cancer tumors evolve and evade targeted therapies.
-
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
-
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
-
REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with...